SCHEMBL5267967

SCHEMBL5267967

CC(C)(C)OC(=O)NC1CCc2cc(C#N)ccc21

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.52
SIRT2 Q8IXJ6 1/20 0.42
SIRT1 Q96EB6 1/20 0.42
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
KDM4D Q6B0I6 4/20 0.40
EGLN2 Q96KS0 1/20 0.40
LRRK2 Q5S007 1/20 0.39
PPARD Q03181 1/20 0.39
PPARA Q07869 1/20 0.39
EPAS1 Q99814 1/20 0.39
BDKRB1 P46663 1/20 0.38
AAK1 Q2M2I8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21178333 1.00 DRD2 (0.52) DRD2SIRT2SIRT1ALDH1A1LMNA
SCHEMBL31130047 1.00 DRD2 (0.52) DRD2SIRT2SIRT1ALDH1A1LMNA
SCHEMBL4049287 1.00 DRD2 (0.52) DRD2SIRT2SIRT1ALDH1A1LMNA
SCHEMBL21178487 0.93 LMNA (0.50) DRD2SIRT2SIRT1ALDH1A1LMNA
SCHEMBL24817021 0.83 TRPV1 (0.47) LMNACA12CA1CA2CA7
SCHEMBL31303024 0.83 TRPV1 (0.47) LMNACA12CA1CA2CA7
SCHEMBL31302986 0.83 TRPV1 (0.47) LMNACA12CA1CA2CA7
SCHEMBL8185532 0.83 TRPV1 (0.47) LMNACA12CA1CA2CA7
SCHEMBL31303000 0.83 TRPV1 (0.47) LMNACA12CA1CA2CA7
SCHEMBL3304298 0.83 CA1 (0.44) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023015184-A1 PROCESS FOR PREPARING AFICAMTEN CYTOKINETICS, INC. (US) 2023-02-09 WO disclosed
EP-1843820-A1 MULTICYCLIC BIS-AMIDE MMP INHIBITORS Alantos Pharmaceuticals, Inc. (US) 2007-10-17 EP disclosed
WO-2006083454-A1 MULTICYCLIC BIS-AMIDE MMP INHIBITORS ALANTOS PHARMACEUTICALS, INC. (US) 2006-08-10 WO disclosed
US-20060173183-A1 Multicyclic bis-amide MMP inhibitors ALANTOS PHARMACEUTICALS, INC., 2006-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060173183-A1 Multicyclic bis-amide MMP inhibitors MMP13, MMP3, MMP11 DRD2 3655/4885SIRT2 557/4885SIRT1 517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.